Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04990427 · ClinicalTrials.gov registry record · Phase 1
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
A Phase 1 study, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04990427: Completed Phase 1 study, sponsored by Lisata Therapeutics.
NCT04990427 is a Phase 1 study that has completed, run by Lisata Therapeutics. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04990427, a Phase 1 study, has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
Primary Outcome
Proportion of patients with a treatment-emergent serious adverse event
Interventions
- DRUG CLBS201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2023-01-26 |
| Phase | Phase 1 |
What the finished NCT04990427 record still lists
NCT04990427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which CLBS201 is the first listed.
NCT04990427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04990427 about?
NCT04990427 is a clinical study titled "CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)". CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
What is the current status of trial NCT04990427?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-01-10. Estimated completion is 2023-01-26.
What interventions are being tested in trial NCT04990427?
The interventions under investigation include: CLBS201 (DRUG).
Who is sponsoring clinical trial NCT04990427?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04990427's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI